EurActiv Logo
EU news & policy debates
- across languages -
Click here for EU news »
EurActiv.com Network

BROWSE ALL SECTIONS

EU companies increase R&D investment despite crisis

Published 17 November 2009
Printer-friendly versionSend by email

European firms increased investment in industrial research and development by more than their US or Japanese competitors last year, despite battling a global economic crisis. 

Worldwide spending on corporate R&D increased by 6.9% in 2008, according to the EU Industrial R&D Investment Scoreboard published yesterday (16 November). 

For companies with their headquarters in the EU, investment growth was 8.1% higher than the previous year. This was a significantly greater increase than the 5.7% growth recorded by US firms and the 4.4% increase recorded in Japan. 

Two European companies feature in the top ten for industrial R&D investment, with Volkswagen coming in third place and Nokia coming eighth. Topping the table was Toyota, which spent €7.61 billion. 

US firms were, on average, more conservative than their European competitors, but American firms still account for half of the top ten corporations when it comes to R&D investment: namely Microsoft, General Motors, Pfizer, Ford and Johnson & Johnson. Switzerland also had two companies in the top tier – Roche and Novartis. 

Companies based in emerging economies continued to show the highest R&D growth, led by China with a 40% increase, India (27.3%), Taiwan (25.1%) and Brazil (18.6%). This is line with expectations that China and India could overtake Europe and the US to become world leaders in research by 2025 (EurActiv 25/09/09).

While R&D spending may have remained robust in 2008, the Scoreboard also provides details of company operating profits, which fell by 30.5% in the EU and 19.1% in the US. 

Pharma and biotech lead the way 

Research growth in the US is dominated by knowledge-intensive sectors, including pharmaceuticals, biotechnology and IT, while R&D growth in the EU is more evenly spread across all sectors. 

EU companies lead the way in the medium-high and medium-low R&D intensity areas, such as the car parts, electrical equipment and chemicals sectors. 

The pharmaceuticals and biotechnology sector reinforces its position as the top R&D investor both worldwide and in the US, accounting for 18.9% and 25% respectively. 

The automobiles and parts sector is the third biggest worldwide, accounting for 17.1%, but the first in EU and Japan, accounting for 25% and 27% respectively. Despite being the first sector to be hit by the economic crisis, some automobile companies recorded double-digit R&D growth in the past year. 

Volkswagen increased investment by 20.4%, Peugeot by 14.4% and Fiat by 14.1%. However, others reduced their R&D investment considerably, including Renault (-9.2%), Daimler (-9.1%), BMW (-8.9%), Ford Motors (-2.7%), and General Motors (-1.2%). 

This year's Scoreboard also confirms the strong R&D activity of companies active in renewable energy technologies. The six EU companies from this sector showed impressive growth in R&D investment over the last three years. 

Positions: 

European Science and Research Commissioner Janez Potočnik said it was good news that EU companies had kept up their R&D investment against the background of the economic crisis in 2008. 

"This is the best strategy to emerge stronger out of the crisis. We must support EU companies' efforts and provide incentives to reinforce the EU's research-intensive sectors. Building a truly European research area is part of the answer, together with EU actions to promote smart investments in R&D. I also welcome the increase of R&D investment by EU companies active on low-carbon energy technologies. They represent new sources of EU growth and jobs," he said. 

Background: 

The 2009 EU Industrial R&D Investment Scoreboard provides information on the top 1,000 EU companies and 1,000 non-EU companies investing in R&D. 

Sustaining research spending has been a major priority during the economic crisis, with experience suggesting countries that manage to invest in innovative industries and basic research fare better in the longer term. 

However, with government budgets running up heavy deficits since 2008 and the private sector seeing its margins squeezed, this has proven challenging. 

Recent figures from Europe and the US suggest the number of new patents being filed has fallen recently, with patent numbers tending to lag 12 months behind the economic trend (EurActiv 06/11/09).

More on this topic

More in this section

Advertising